STOCK TITAN

Xenon Pharmaceut reported $7.5M in revenue and a $345.9M net loss for fiscal 2025. See the full XENE financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Xenon to Present at Wells Fargo Healthcare Conference

Xenon Pharmaceuticals will host a webcast fireside chat at the Wells Fargo Healthcare Conference, with replay access available for investors after the event.

(Neutral)
(Positive)
Tags

Xenon Pharmaceuticals (XENE) plans to present at the Wells Fargo Healthcare Conference in Boston, MA, via a fireside chat scheduled for Wednesday, September 9, from 11:00 to 11:30 am ET.

Details and a live webcast link will be available in the Investors section of Xenon’s website, with a replay posted after the event, subject to possible schedule changes.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

In the provided market data, RARE was up 2.2% while XENE was up 0.27% before the headline. The confe...
Analysis

In the provided market data, RARE was up 2.2% while XENE was up 0.27% before the headline. The conference notice added timing, not clinical or financial results; recent insider activity was net selling.

Key Figures

Announcement Date: September 3, 2026 Conference Date: September 9 Fireside Chat Time: 11:00–11:30 am ET +1 more
4 metrics
Announcement Date September 3, 2026 News announcement
Conference Date September 9 Wells Fargo Healthcare Conference
Fireside Chat Time 11:00–11:30 am ET September 9 presentation
Development Stage Phase 1 Early-stage potassium and sodium channel modulator programs

Historical Context

5 past events · Latest: Aug 28 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 28 Inducement grants Neutral +0.4% Equity awards granted to five new non-officer employees under Nasdaq rules.
Aug 26 Phase 3 data Positive -2.9% Company announced upcoming Phase 3 epilepsy data and additional scientific presentations.
Aug 06 Q2 results Negative -1.8% Quarterly report included no revenue, a net loss, and ongoing development updates.
Jul 31 Inducement grants Neutral -0.7% Equity awards granted to eleven new non-officer employees under Nasdaq rules.
Jul 30 Results scheduling Neutral -2.4% Company scheduled its Q2 2026 financial-results release and business update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were negative for four of five selected general-news events; the only positive reaction was 0.38%.

Key Terms

kv7 potassium channel opener, nav1.7
2 terms
kv7 potassium channel opener technical
"azetukalner, is a novel, potent KV7 potassium channel opener"
A Kv7 potassium channel opener is a drug that helps certain cellular ‘gates’ called Kv7 channels stay open so potassium can flow out of cells, calming electrical activity in nerves and muscle. For investors, these compounds matter because they can form the basis of treatments for conditions driven by excessive electrical firing—like some seizures, pain, or heart rhythm disorders—so successful candidates can create new medical markets or reduce risks in drug pipelines.
nav1.7 technical
"including KV7 and NaV1.7 programs in Phase 1 development"
NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:

  • Wells Fargo Healthcare Conference, Boston, MA
    Fireside Chat: Wednesday, September 9, 11:00–11:30 am ET

Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc. 

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. 

Contacts: 

For Investors:  
Tucker Kelly  
Chief Financial Officer  
investors@xenon-pharma.com  

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
media@xenon-pharma.com  


FAQ

When will Xenon Pharmaceuticals (XENE) present at the Wells Fargo Healthcare Conference?

Xenon Pharmaceuticals is scheduled to present at the Wells Fargo Healthcare Conference in Boston, MA, on Wednesday, September 9, during a fireside chat from 11:00 to 11:30 am ET, although the company notes that dates and times are subject to change.

How can investors access the Xenon Pharmaceuticals (XENE) Wells Fargo Healthcare Conference webcast?

Webcast details for Xenon Pharmaceuticals’ fireside chat at the Wells Fargo Healthcare Conference will be available in the Investors section of the company’s website, where a replay will also be posted after the event when available.

Will a replay of Xenon Pharmaceuticals (XENE) Wells Fargo Healthcare Conference presentation be available?

Yes. Xenon Pharmaceuticals indicates that webcasts of its Wells Fargo Healthcare Conference presentation will be posted for replay following the event in the Investors section of its website, once available.

Where is Xenon Pharmaceuticals (XENE) headquartered and what is its therapeutic focus?

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company with offices in Vancouver, British Columbia, and Boston, Massachusetts. It is dedicated to drug discovery, clinical development, and commercialization of therapeutics targeting epilepsy, mood disorders, and pain.